Federal Medical Marijuana Acceptance Leaves Implementation Unclear

Agency Acknowledgments Lack Coordinated Framework

The DEA, FDA, and HHS have recognized medical marijuana's therapeutic value in recent guidance, but those acknowledgments remain siloed and uncoordinated. The DEA's May 2025 notice of proposed rulemaking on rescheduling cannabis to Schedule III referenced HHS findings that marijuana has accepted medical use, reversing the agency's longstanding position. The FDA's February 2026 guidance to institutional review boards eased restrictions on cannabis clinical trials, citing "evolving scientific understanding." HHS Secretary Xavier Becerra told a Senate appropriations subcommittee in April 2026 that his department "no longer disputes" marijuana's medical applications in certain conditions.

These statements don't establish a legal pathway for physicians to prescribe cannabis under federal law or for pharmacies to dispense it across state lines. The Controlled Substances Act still prohibits marijuana distribution outside FDA-approved drug products, of which only three cannabinoid formulations currently exist: Epidiolex, Marinol, and Syndros. The gap between rhetorical acceptance and operational law keeps widening.

Schedule III Rescheduling Does Not Authorize Prescriptions

If the DEA finalizes its proposed Schedule III rescheduling, marijuana would remain a controlled substance requiring FDA approval for any product intended for human use. Schedule III drugs such as ketamine and anabolic steroids are prescribed under strict DEA registration and state medical board oversight. Marijuana's rescheduling wouldn't automatically grant state-licensed dispensaries federal legitimacy, because dispensaries don't operate under the FDA's New Drug Application process.

The rescheduling proposal, published in the Federal Register on May 16, 2025, drew more than forty-seven thousand public comments during its initial comment period. The DEA extended that period twice. No final rule date has been announced. Administrative law experts anticipate the final rule won't take effect before the third quarter of 2026 at the earliest. Even then it won't resolve the prescription question. Physicians would still face federal prosecution risk for recommending cannabis outside FDA-approved formulations, though enforcement likelihood is low given DOJ's current de-prioritization policy.

Research Access Remains Bottlenecked Despite Rhetoric

Federal officials have called for expanded cannabis research, yet the Drug Enforcement Administration has licensed only four additional bulk marijuana manufacturers since 2021. The University of Mississippi's National Center for Natural Products Research held a monopoly on federally legal research cannabis from 1968 until 2021. The DEA approved three private cultivators in December 2021 and one more in March 2023, but production delays and quality complaints from researchers have persisted.

Dr. Sue Sisley, president of the Scottsdale Research Institute, told a House Energy and Commerce subcommittee in January 2026 that her team waited nineteen months for a shipment of research-grade flower from a newly licensed supplier. The material arrived with visible mold contamination and cannabinoid potency fifteen percent below the certificate of analysis, according to third-party lab results Sisley submitted to the committee. The FDA's February 2026 IRB guidance encouraged institutions to approve cannabis studies. But researchers report the supply chain hasn't scaled to meet demand.

Interstate Commerce Prohibition Unchanged

No federal statute or regulation currently permits cannabis products to cross state lines, even between states with legal medical programs. The Cole Memorandum, rescinded in 2018, had deprioritized federal enforcement against state-compliant operators but never affirmatively authorized interstate transfers. The 2018 Farm Bill legalized hemp with delta-9 THC concentrations below 0.3 percent by dry weight, creating a legal interstate market for CBD and other hemp cannabinoids. Marijuana products above that threshold remain per se illegal under the CSA for purposes of interstate transport.

Multi-state operators such as Curaleaf, Trulieve, and Green Thumb Industries maintain separate cultivation and processing facilities in each state where they hold licenses, duplicating capital expenditures to avoid federal trafficking charges. Industry analysts estimate that interstate commerce legalization would reduce MSO operating costs by eighteen to twenty-three percent through supply chain consolidation, according to a February 2026 report by Viridian Capital Advisors. No bill currently before Congress would authorize such commerce. The SAFE Banking Act, reintroduced in the 119th Congress as H.R. 1996, addresses only financial services access and doesn't touch the interstate question.

Patient Protections Absent in Federal Employment and Benefits

Federal employees and contractors remain subject to termination for state-legal medical marijuana use, and veterans cannot access cannabis through the Department of Veterans Affairs. The Office of Personnel Management's drug-free workplace policy, last updated in August 2023, states that marijuana use "remains illegal under federal law" and is grounds for adverse action regardless of state medical authorization. Approximately 2.3 million federal civilian employees and an estimated 4.1 million contractor personnel fall under this prohibition.

The VA issued a directive in July 2024 clarifying that its clinicians may discuss marijuana use with patients and document it in medical records without penalty, but the department can't prescribe, dispense, or reimburse cannabis under Title 38. Veterans in the VA health system who use state-legal medical marijuana must pay out of pocket and risk losing access to certain controlled medications, particularly opioids, if their provider deems concurrent use unsafe. Advocacy groups including Veterans Action Council and Iraq and Afghanistan Veterans of America have lobbied for a carve-out in VA policy. No regulatory change has been proposed.

What Happens Next Depends on Congressional Action

Administrative agencies can't resolve the core legal conflicts without statutory changes from Congress, and no comprehensive federal medical marijuana bill has advanced past committee in the current session. The MORE Act, which would deschedule cannabis entirely, passed the House in April 2024 but stalled in the Senate. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer in July 2023, hasn't received a floor vote. Both bills would establish federal regulatory frameworks, but neither is expected to pass in the 119th Congress given divided control and competing legislative priorities.

Absent congressional movement, the federal posture on medical marijuana will remain a patchwork of agency memos, enforcement discretion, and unresolved legal ambiguities. The DEA's rescheduling decision, when finalized, will be the most significant federal policy shift in fifty years. It won't answer the operational questions that patients, providers, and businesses face daily.

The next forcing event is the DEA's final rule on Schedule III. If published by September 2026, legal challenges will follow within weeks. The D.C. Circuit will likely hear the first consolidated case, with a decision timeline extending into 2027. We'll be watching whether the agency addresses prescription authority in the final rule or leaves that question for Congress and the courts.